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Abstract
Background: Short-term OE (oleoyl-estrone) treatment causes significant decreases in rat weight
mainly due to adipose tissue loss. The aim of this work was to determine if OE treatment affects
the expression of genes that regulate lipid metabolism in white adipose tissue.
Results: Gene expression in adipose tissue from female treated rats (48 hours) was analysed by
hybridization to cDNA arrays and levels of specific mRNAs were determined by real-time PCR.
Treatment with OE decreased the expression of 232 genes and up-regulated 75 other genes in
mesenteric white adipose tissue. The use of real-time PCR validate that, in mesenteric white
adipose tissue, mRNA levels for Lipoprotein Lipase (LPL) were decreased by 52%, those of Fatty
Acid Synthase (FAS) by 95%, those of Hormone Sensible Lipase (HSL) by 32%, those of Acetyl CoA
Carboxylase (ACC) by 92%, those of Carnitine Palmitoyltransferase 1b (CPT1b) by 45%, and those
of Fatty Acid Transport Protein 1 (FATP1) and Adipocyte Fatty Acid Binding Protein (FABP4) by
52% and 49%, respectively. Conversely, Tumour Necrosis Factor (TNFα) values showed
overexpression (198%).
Conclusion: Short-term treatment with OE affects adipose tissue capacity to extract fatty acids
from lipoproteins and to deal with fatty acid transport and metabolism.
Background
Experimental administration of Oleoyl-estrone (OE)
induces the selective loss of body fat, without concurrent
loss of body protein [1,2]. Since OE is synthesized from
estrone by adipose cells [3] and released into the blood-
stream, where its concentrations correlates with body fat
mass [4,5], OE has been postulated as a lipostatic signal
regulating body fat mass. The short-term effects of OE
treatment in rats, involve the decrease in food intake, a
decrease in body weight and an impressive decrease of
cholesterol levels, mainly due to the sharp decrease of
HDL-cholesterol that results in an increased cholesterol
turnover rate [6]. This pattern has been reproduced also in
obese humans [7]. The selective fall in total fat content is
a direct consequence of the generalized decrease of adi-
pose tissue mass in several locations [8].
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doses of oleoyl-estrone causes mild estrogenic effects, and
results in high circulating levels of estrone [9]. Oral
administration of the estrone ester, however, prevents
these effects by maintaining low plasma levels of both
estrone and estradiol. Furthermore, oral OE treatment
does not increase the total body estrogen content of the
rat [10]. The lack of noticeable estrogenic effects has been
confirmed when an obese man used OE treatment for lose
weight without secondary effects [7]. At the moment, the
mechanism underlying oleoyl-estrone action remains
unknown. In this respect, the involvement of receptors
different from classic estrogen receptors has been pro-
posed [9], although it seems that the mechanism involves
pathways other than those activated by forced food
restriction, as pair-fed models [11].
It seems evident, however, that the OE action must be
related with the ability of white adipose tissue to manage
lipidic compounds. For this reason, the objective of the
present work was to determine if a short-term OE treat-
ment, in spite of its effects on food intake, caused signifi-
cant changes in the expression of genes that regulate lipid
metabolism in white adipose tissue.
Results
Wistar rats were subjected to an oral treatment with ole-
oyl-estrone. After 48 hours, their body weight and food
intake were determined as well as the levels of different
metabolites in serum (Table 1). Treated animals showed
significant lower percentages of body weight variation
than controls, together with a noticeable decrease in food
intake. Plasmatic levels of metabolites did not present
important changes in treated animals, except for choles-
terol and HDL-cholesterol that showed significant
decreases compared to the controls.
The expression profile of the 1168 genes included in the
specific Atlas Rat Array 1.2 (Clontech) was analyzed in the
mesenteric white adipose tissue from control animals and
treated with oleoyl-estrone. Treatment with OE decreased
the expression of 232 genes and up-regulated 75 other
genes in mesenteric white adipose tissue. Table 2 shows
18 down-regulated and 7 up-regulated selected genes that
expressed a ratio lower than 0.5 or higher than 1.50 when
compared with control group in mesenteric white adipose
tissue. FAS, ACC, FABP4, LPL, CPT1b, HSL and FATP1
showed ratios lower than 0.40. The differentially
expressed genes were classified according to their function
in several categories and their role in the intermediate
metabolism, as Complex Lipid Metabolism, Simple Lipid
Metabolism, Other Traffiking & Targeting Proteins, etc.
These data are deposited in Gene Expression Omnibus
(GSE8538).
Next, we proceeded to validate the differential expression
of specific outlier genes to verify the changes in mRNA lev-
els. Real-time PCR offers a non hybridization-based detec-
tion and was chosen as complementary to arrays. The
selected genes were analyzed by real-time PCR under the
same experimental conditions as for the Array analyses.
In mesenteric white adipose tissue (Figure 1), it was deter-
mined that mRNA levels for HSL were decreased by 32%,
whereas those of FAS, ACC and CPT1b were decreased by
a 95%, 92% and 45% respectively upon treatment with
OE. In the Figure 2 can be seen that treatment with OE
decreases mRNA expression of FATP1 by 52%, FABP4 by
49% and LPL by 52%. Conversely, TNFα showed overex-
pression (198%) as a consequence of OE-treatment. All
these changes were statistically significant (p < 0.05),
except for HSL and TNFα. These results confirmed the
RNA data obtained in the screening performed using the
cDNA arrays.
Discussion
The application of genomic technologies to study differ-
ent metabolic profiles has been widely used [12-14], espe-
cially in the case of adipose tissue or obesity. The
application of this miniaturized hybridization technology
allows the simultaneous analysis of the expression of hun-
dreds of genes and pride the opportunity to discover
abnormalities in the expression of many genes. In this
case, the experience has been positive, since we have
detected many genes underexpressed, and a more reduced
amount of overexpressed genes, as a consequence of OE
treatment. A minimal part of this abundant information
has been shown in the Table 2, and we have only used
which referred to lipid metabolism.
The short-term treatment with OE reproduced the pattern
previously described [6], where the decrease caused in
body weight, food intake and in HDL-cholesterol levels
were the main traits. Under these standard conditions, we
were able to determine the gene expression profile in tis-
sue samples extracted from OE-treated animals and con-
firm by real-time PCR the changes in the expression of
some specific genes. In the mesenteric white adipose tis-
sue were selected different enzymes implied either in stor-
age or in the mobilization of lipids; LPL as a main
inductor of fatty acid uptake from lipoproteins; FATP1
and FABP4 implied in fatty acid transport across the mem-
brane and citosol respectively; ACC and FAS as regulatory
enzymes in the synthesis of fatty acids; HSL as main
responsible for triacylglycerol mobilization and CPT1b as
a regulatory pathway for beta-oxidation. Furthermore,
TNFα, a regulatory peptide that exerts an important con-
trol on tissue proliferation and the uptake and storage of
metabolites was also selected.Page 2 of 8
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ysis of circulating triglycerides (in chilomicra and VLDL
lipoproteins) into free fatty acids and glycerol and plays a
major role in adipocyte lipid storage and hence the regu-
lation of obesity [15]. LPL is thought to act as a "gate
keeper" for fatty acid uptake into organs [16], in spite that
other pathways must be implied, because both humans
and mice without adipose tissue LPL, still have some
essential fatty acids in adipose tissue [17]. The under
expression of LPL by OE-treatment is consistent with the
previously described loss of weight, that is a consequence
of decrease in adipose tissue weight [8]. Thus, if adipose
tissue has lost some capacity to extract lipid from circulat-
ing lipoproteins, a decrease in the accumulation of lipids
will be the immediate consequence. An inhibitory action
of estrogens on lipoprotein lipase has been described to
explain the inhibition of obesity development by estrogen
replacement therapy in rats [15]; however, we do not have
any evidence that support a similar action for the inhibi-
tory effect of OE treatment. Furthermore, the underexpres-
sion of LPL could be also influenced by TNFα
overexpression [18], due to its inhibitory action on LPL
expression.
The decreased expression of fatty acid transport proteins
(FATP1 and FABP4) confirms the previous statement, and
then a low capacity to release fatty acids from lipoproteins
is completed with a decreased transport into the cell (low
FATP1 expression), that is accordance with the strength of
their expression and the appearance of obesity [19]. Fur-
thermore, the decrease in FABP4 expression is in accord-
ance with a decrease in fatty acid utilization, and may be
a consequence of the decreased food intake, as FABP4
seems to be up regulated by diet [20].
Lipogenesis implies the synthesis of fatty acids from non
lipid substrates and is played in liver and adipose tissue
and is under control of hormones and metabolites from
dietary origin. Thus, insulin and glucose activate the lipo-
genic pathway, and conversely, glucagon and poly-
unsaturated fatty acids inhibits this process [21]. These
regulatory actions may imply the action of different tran-
scription factors and nuclear receptors, in spite of the
noticeable differences between human and rodent adi-
pose tissues [22]. Fatty acid synthase activity and their
mRNA expression are usually taken as markers of lipogen-
esis [23], since the alterations in activity are due primarily
to alterations in the transcription rate. A sharp decrease in
the expression of FAS, as in OE-treated rats, will imply an
important decrease in its activity, and then a decrease in
the synthesis de novo of fatty acids in adipose tissue. More-
over, the decrease in the expression of ACC may act rein-
forcing the slowing of fatty acid synthesis pathway.
However, it must be taken into account the dual action of
ACC, since the increase of their activity can act as a precur-
sor of malonyl CoA as an inhibitor of mitochondrial
translocation of fatty acids to beta-oxidation [24].
The decreased capacity to catabolize fatty acid can be a
consequence both of a decrease in adipose tissue ability to
degrade triacylglycerols and a decrease in the beta-oxida-
tion pathway. Thus, a clear tendency to decrease in the
expression of HSL, as HSL activity regulates lipolytic path-
way [25], must be interpreted as adipose tissue reduces the
hormone-dependent triacylglycerol degrading capacity.
Furthermore, the passage of fatty acids to mitochondria is
compromised as the expression of carnitine palmitoyl-
transferase 1b (CPT1b) shows a low expression level.
Since CPT1b is the isoform present in adipose tissue [26],
regulates the entrance to oxidation pathway, in spite of
the low activity attributed to white adipose tissue [27], its
low expression levels emphasizes the general trend to
show low fatty acid oxidation rates as a consequence of
OE-treatment. Moreover, this low pace activity can be
reinforced by the inhibition caused by malonyl-CoA, that
could be accumulated as a consequence of decreased FAS
expression, since its decrease is faster than that of ACC
(the expression of ACC has been reduced to 0.47 with 24-
Table 1: Weight change, food intake and plasma parameters of 
Wistar rats at 48-hours after the onset of an oral treatment with 
oleoyl-estrone (OE)
Parameter Group Mean ± SEM
Body weight (% of 
initial)
Control 101 ± 0.89
OE 96.8 ± 0.76 *
Cumulative food 
intake (g)
Control 42.9 ± 2.11
OE 29.7 ± 2.61 *
Glucose (mM) Control 7.72 ± 0.20
OE 7.65 ± 0.31
Total Cholesterol 
(mM)
Control 1.48 ± 0.13
OE 0.88 ± 0.04 *
HDL-cholesterol 
(mM)
Control 0.98 ± 0.14
OE 0.22 ± 0.02 *
HDL/total 
cholesterol ratio (%)
Control 66.2 ± 7.21
OE 23.7 ± 2.05 *
Non-esterified fatty 
acids (mM)
Control 0.56 ± 0.08
OE 0.60 ± 0.04
3-hydroxybutyrate 
(mM)
Control 0.28 ± 0.02
OE 0.30 ± 0.06
Triacylglycerols 
(mM)
Control 0.91 ± 0.09
OE 0.79 ± 0.10
The data are the mean ± SEM of data from six animals per group. 
Statistical comparison between groups was determined using the 
Student's t test. * = P < 0.05Page 3 of 8
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0.17 (data not shown).
Tumour necrosis factor-α (TNFα) can act both as auto-
crine or a paracrine factor, playing a central role in the
control of production of several cytokines or acute phase
proteins [28]. TNFα synthesis in adipose tissue occurs in
stromal vascular and matrix fraction including macro-
phages. TNFα plays a main role in the inflammatory state
that is characteristic of obesity, and the increase in its lev-
els may be related with the inhibitory effect on insulin
receptor signalling pathway, the diminishing triacylglyc-
erol depots in adipose tissue or in the development of
apoptosis [28]. Thus the tendency to increase the expres-
sion of TNFα could strengthen different mechanisms that
will achieve with the decrease of lipidic depots in white
adipose tissue, inhibiting the action of insulin and pro-
moting the apoptosis, in spite of their inability to pro-
mote an increased HSL response. The different sensitivity
to OE treatment in different adipose tissue sites [29], and
the selectively different response of OE treatment in front
of a single food deprivation [11], must be taken into
account to infer that this treatment induces a tendency to
increase the TNFα expression that can collaborate with the
global process of lipid mobilization, probably through
the stimulation apoptotic pathways, since a generalized
increase in apoptosis markers has been described as a con-
sequence of OE-treatment [29].
Conclusion
Short-term treatment with OE affects the capacity of adi-
pose tissue to extract fatty acids from lipoproteins
(decrease in LPL expression), to transport fatty acids
(decreases in FABP and FATP), to generate fatty acids from
precursors (decrease in ACC and FAS expression) and to
catabolize their fatty acids (decreases in CPT1b expres-
sions), where the global process is controlled by regulator
factors such as TNFα. This impaired ability to obtain
Table 2: Genes that are differentially expressed in mesenteric white adipose tissue of OE-treated rats
Ratio GeneBank Functional Classification
Down-regulated genes
Fatty acid synthase (FAS) 0.11 M76767 Metabolism of cofactors, vitamins & related substances
Acetyl-CoA carboxylase (ACC) 0.19 J03808 Simple Lipid metabolism
Prostaglandin d2 receptor 0.30 U92289 Hormone Receptors
Fatty acid transport protein (FATP1) 0.31 U89529 Other membrane channels & Transporters
Very long chain acyl-coa dehydrogenase (vlcad) 0.32 D30647 Metabolism of Cofactors, Vitamins & Related Substances
Lipoprotein lipase (LPL) 0.33 L03294 Complex Lipid Metabolism
Slow voltage-gated potassium channel protein 0.33 M22412 Voltage-gated ion channels
Low density lipoprotein receptor 0.35 X13722 Other receptors
Pyruvate dehydrogenase kinase kinase 0.37 L22294 Intracellular kinase network members
Adipocyte fatty acid-binding protein (FABP4) 0.38 U75581 Other Trafficking & Targeting proteins
Carnitine palmitoyltransferase 1b (CPT1b) 0.39 D43632 Simple Lipid metabolism
Hormone-sensitive lipase (HSL) 0.40 U40001 Simple Lipid Metabolism
Cytochrome P450 2c7 0.42 M18335 Complex Lipid Metabolism
Glucose-6-P-dehydrogenase 0.45 X07467 Complex Carbohydrate Metabolism
Retinoid X receptor beta 0.45 M81766 Nuclear receptors
Brain fatty acid binding protein 0.45 U02096 Other Trafficking & Targeting proteins
Adenyl cyclase 0.46 M80633 Adenylate/Guanylate Cyclases & Diesterases
Proteasome 26s subunit 2 0.47 D50694 Proteosomal Proteins
Up-regulated genes
Insulin receptor-related receptor alpha subunit 1.52 M90661 Intracellular Kinase network members
Cytochrome p450 4f5 1.72 U39207 Complex Lipid Metabolism
Tumor necrosis factor alpha (TNFα) 1.77 X66539 Growth Factors, Cytokines hemokines
GTP-binding protein 1.82 L19699 G Proteins
Ras-gtpase activation protein 1.85 L13151 GTP/GDP exchangers & GTPse activity modulators
Cytochrome p450 4b1 2.01 M29853 Other Metabolism Enzymes
Protein arginine n-methyltransferase 1 3.59 U60882 Intracellular Adaptors eceptor Associated Proteins
The expression of each gene is reported as the ratio of the value obtained after each treatment relative to control after normalization of the data.Page 4 of 8
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them in adipose tissue are key observations of the initial
tracks to establish the mechanism of action of OE.
Methods
Animals
Female Wistar rats (Harlan-Interfauna Ibérica, Sant Feliu
de Codines, Spain) weighing initially 220–230 g were
housed in individual cages under a light cycle (on from
08.00 to 20.00) and in a temperature-controlled environ-
ment (20–22°C). Food (standard rat chow pellets, from
Panlab, Barcelona, Spain) (available energy: 13.6 MJ/kg)
and water were provided ad libitum.
All procedures were in accordance with the guidelines for
the use of experimental animals established by the EU,
Spain and Catalonia, and were approved by the Animal
Handling Ethics Committee of the University of Barce-
lona.
Treatment
The rats were given a daily oral gavage of 10 μmol/kg/day
of oleoyl-estrone (OED, Barcelona, Spain) in 0.2 ml of
sunflower oil during two days, by means of stomach can-
nulae. Controls received only the oil gavage.
Tissue samples and plasma determinations
After 48 hours of the beginning of treatment, fed rats were
killed by decapitation and blood was recovered in plastic
beakers. Serum was separated and frozen for analysis. The
mesenteric white adipose tissue was also dissected and
frozen in liquid nitrogen and stored at -80°C. This adi-
pose location was used as showed the higher sensitivity to
OE treatment [29].
The serum was later used for the measurement of total
cholesterol (Menarini, Firenze, Italy), HDL-cholesterol
using the same kit after using the HDL-cholesterol precip-
itant rat reagent (Randox, Crumlin, UK), glucose (Sigma,
St. Louis MO, USA), non-esterified fatty acids (Wako,
Richmond VA, USA), 3-hydroxybutyrate (Roche, Man-
nheim, Germany) and total triacylglycerols (Biosystems,
Barcelona, Spain).
RNA isolation
Total RNA was extracted from adipose mesenteric tissue
using Tripure isolation kit (Roche). RNA concentration
and quality were measured by spectrophotometric analy-
sis at 260 nm and 280 nm using Nanodrop equipment
(Wilmington DE, USA). RNA integrity was assessed by
electrophoresis in agarose gel.
cDNA arrays
Gene expression was analysed by hybridization to cDNA
arrays (Atlas™ Rat Array 1.2 from BD-Clontech, Mountain
View CA, USA). We selected this array because it was spe-
cific for rat and included genes implied in multiple meta-
bolic actions, fact that was appropriate for an initial
screening of OE action. Radiolabeled cDNA probes were
prepared from 5 μg of total RNA. Briefly, the RNA was
incubated for 2 min at 70°C followed by 2 min at 50°C
with 1 μl of the primer mix, containing the 1168 primers
for the genes presented in the array. The RT reaction was
carried out using 100 U MMLV-RT, 40 U RNAsin
(Promega, Madison WI, USA) and 35 μCi [α-33P] dATP
(Amersham Biosciences, Piscataway NJ, UK) for 25 min at
50°C. Labeled cDNA was purified from unincorporated
nucleotide with Atlas NucleoSpin® Extraction Kit (Clon-
tech). Nylon membranes were pre-hybridized in
ExpressHyb™ (Clontech) with 100 μg/ml DNA salmon
sperm for 30 min in an oven at 68°C. Then, the 33P-
labeled probe was added and hybridization continued
overnight at the same conditions. Afterwards, membranes
were washed lowering the astringency progressively to 0.1
× SSC, 0.5% SDS at 68°C and placed in contact with euro-
pium screens (Kodak, Rochester NY, USA) for 15 days.
The screens were scanned with a Storm 840 phosphorim-
ager (Molecular Dynamics, Sunnyvale CA, USA).
Array data analysis
Image analysis and quantification were carried out with
Atlas Image 2.01 software (Clontech). After grid assign-
ment, the adjusted intensity for each gene was calculated
by subtracting the background. This value was used as the
input for the GeneSpring 6.1 program (Agilent, Palo Alto
CA, USA), that allows normalization of data analysis from
different experiments, the generation of restriction lists,
and the functional classification of the differentially
expressed genes. Normalization was applied in two steps:
(i) 'per chip normalization', where each data point was
divided by the 50th percentile of all measurements in its
array and (ii) normalization of each sample against the
median of the control samples. The expression of each
gene is reported as the ratio of the value obtained after
each treatment relative to control after normalization of
the data. Then data were filtered using the control
strength, a control value calculated using the Cross-Gene
Error Model based on replicates. Measurements with
higher control strength are relatively more precise than
measurements with lower control strength. Genes that
didn't reach this value were discarded. Lists of differen-
tially expressed genes considering a 1,5 or 0.5 fold expres-
sion were generated using data from 2 animals for each
condition. These cutoffs of 1.5 or 0.5 were chosen given
that small changes in gene expression may represent
important changes downstream of those differentially
expressed genes. The genes in these lists were further clas-
sified according to their function.Page 5 of 8
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The selected targets for real-time PCR were LPL, FAS, HSL,
FABP4, FATP1, ACC, CPT1b and TNF-α. Specific mRNA
levels were determined by semi-quantitative real-time
PCR. To disrupt the potential formation of secondary
structures, 2 μg total RNA and 40 μg oligo dT primers
(Roche) in 10 μl were incubated for 5 min at 70°C and
then chilled on ice. Complementary cDNA was synthe-
sized by adding to the mixture 200 U MMLV RT
(Promega), 25 U RNAsin (Promega), 0.5 mM dNTPs
(GeneCraft, Lüdinghausen, Germany) and MMLV RT
buffer. Twenty-five μl of reaction mixture was incubated at
42°C for 60 min, with the cDNA product used for subse-
quent PCR amplification with specific primers.
The real-time assay was performed using an iCycler iQ
(Bio-Rad, Hercules CA, USA). Rat FAS, TNFα, ACC,
FABP4, HSL, CPT1b and FATP1 mRNA expressions were
analyzed using SYBR Green and LPL and cyclophilin using
Taq Man methodology. The signals corresponding to the
cyclophilin mRNA were used to normalize the changes in
mRNA levels for each particular case.
Primers from genes analyzed by SYBR Green, were
designed (Primer 3 program) to be exon-spanning to
avoid amplification of genomic DNA. To confirm the
amplicon length PCR products were resolved on 2% agar-
ose gel. Forward and reverse primers sequences for PCR
amplification and the length of the PCR product were:
FAS 5'-CTTGGGTGCCGATTACAACC-3' and 5'-GCCCTC-
CCGTACACTCACTC-3' (185 bp);
TNFα 5'-GGCTCCCTCTCATCAGTTCCA-3' and 5'-GCTT-
GGTGGTTTGCTACGA-3' (104 bp);
ACC 5'-AGGAAGATGGTGTCCCGCTCTG-3' and 5'-
GGGGAGATGTGCTGGGTCAT-3' (145 bp);
FABP4 5'-CCTTTGTGGGGACCTGGAAA-3' and 5'-TGAC-
CGGATGACGACCAAGT-3' (152 bp);
HSL 5'-CCCATAAGACCCCATTGCCTG-3' and 5'-
CTGCCTCAGACACACTCCTG-3' (93 bp);
CPT1b 5'-GTGCTGGAGGTGGCTTTGGT-3' and 5'-
TGCTTGACGGATGTGGTTCC-3' (152 bp);
Quantization of HSL, ACC, FAS, and CPT1b by real-time PCR in samples of mesenteric white adipose tissue of treated rats duri g 48-hours with OEFigure 1
Quantization of HSL, ACC, FAS, and CPT1b by real-time PCR in samples of mesenteric white adipose tissue of treated rats 
during 48-hours with OE. The results express the levels of mRNA, corrected by cyclophilin values and expressed as a percent-
age of controls. Results express the means ± SEM of 4 different experiments. Asterisks indicate differences from controls: * P 
< 0.05.Page 6 of 8
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GAGGATACGGCTGTTG-3' (106 bp).
The PCR mixture (20 μl final volumes) contained 10 ng
cDNA, 1× iQ SYBR Green Supermix (Bio Rad) and 300
nM of forward and reverse primers.
Taq Man primers and probe for LPL (assay ID: Rn
00561482_ml) and cyclophilin (assay ID: Rn
00690933_ml) were assay-on-demand (AoD) gene
expression products selected (Applied Biosystems, Foster
City CA, USA). The PCR mixture (20 μl final volume) con-
tained 10 ng cDNA, 1× iQ Supermix (Bio Rad) and 1×
AoD mixture.
The thermal conditions were: initial denaturation of
cDNA (3 min at 95°C), amplification of target cDNA
(denaturation 30 s at 95°C and 40 cycles of amplification
1 min 60°C). Melting curve analysis for product identifi-
cation and to discard dimmers presence was performed in
the SYBER Green assay.
Statistical methods
Array data analyses were conducted via a parametric com-
parison using all available error estimates as a filter based
on variances calculated by the Cross-gene Error Model in
GeneSpring 6.1 software (Silicon Genetics, Redwood City
CA, USA). The Cross-gene Error Model performs a vari-
ance components analysis for the accurate comparison of
mean expression levels between experimental conditions.
In this model, separate estimates for two different kinds of
random variation are used to estimate the variability in
gene expression measurements: i) measurement variation:
this comprises the lowest level of variation, corresponding
to the variation of gene measurement of a single chip
based on the actual value that would be obtained from a
perfect measurement of the gene expression level for that
sample, and ii) sample-to-sample variation: the variation
between samples under the same condition reflecting bio-
logical or sampling variability.
For real-time PCR analyses, values are expressed as the
mean ± S.E.M. Data were evaluated using the unpaired
Student's t-test and analysis was performed with Prism 4.0
Quantization of LPL, FABP4, FATP1 and TNFα by real-time PCR in samples of mesenteric white adipose tissue of treated rats duri g 48-hours with OEFigure 2
Quantization of LPL, FABP4, FATP1 and TNFα by real-time PCR in samples of mesenteric white adipose tissue of treated rats 
during 48-hours with OE. The results express the levels of mRNA, corrected by cyclophilin values and expressed as a percent-
age of controls. Results express the means ± SEM of 4 different experiments. Asterisks indicate differences from controls: * P 
< 0.05.Page 7 of 8
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ferences in P-values < 0.05 were considered significant.
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